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ABSTRACT
Reported here is the case series of six infants 
presenting with immune reconstitution syndrome 
following the initiation of antiretroviral therapy 
(ARV). The infants had no BCG scars at the time of 
starting ARVs and the mean duration of appearance 
of the cold abscess / lymphadenitis on the ipsilateral 
side of the BCG site was 2 – 8 weeks. Mycobacterial 
speciation studies of the fine needle aspirate 
material showed Mycobacterium Bovis, BCG strain. 
Two of the patients had to require antimycobacterial 
therapy.
INTRODUCTION
In Zambia, Bacille Calmette-Guerin (BCG), a live 
attenuated Mycobacterium bovis strain vaccine, is 
universally given to neonates at birth or shortly 
thereafter in conformity with the recommendations 
1of the World Health Organisation . BCG vaccine is 
given to this population of neonates regardless of 
their HIV status as they are asymptomatic in the 
1early neonatal period . The vaccine coverage rate for 
2BCG currently stands at 95% .
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Antiretroviral (ARVs) therapy has been available in 
selected public health service in Zambia since 2003 
and over the years this has been scaled up to nearly 
3
every health centre . The ARVs are free and are 
principally supplied by the donor community like 
PEPFAR, Clinton Foundation, Global Funds and to 
3
some extent the Zambian Government . Of the 
estimated 76,000 children infected with HIV in 
2010, there are currently well over 23,000 children 
on ARVs of the 34,000 who require treatment in 
3Zambia . 
Voluntary Counseling and Testing (VCT) in 
pregnancy is the cornerstone of Prevention of 
Mother to Child Transmission (PMTCT) of HIV and 
in the urban setting in Zambia acceptability is 
currently put at 70% and is lower in the rural 
4population .  
ETHODS
Site setting: The study was done in one of the 5 
general paediatric units at The University Teaching 
Hospital, Lusaka and the admission rota is 1:5. The 
units manage the patients they admit during their 
emergency admission days and inpatients with 
further follow-ups in review clinics
. 
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HIV Counselors: Nurse counselors stationed in the 
admission ward offer VCT to all parents/guardians 
whose children are admitted to the admission ward.  
Unless they are discharged before VCT, those 
transferred to the wards as in-pateints who were 
missed in admission ward are offered VCT.
Patients:  Dot Blood Sample (DBS) is taken on filter 
paper for HIV I/II DNA PCR by the nurse counselors 
from neonates and young children before 18 months 
of age who are found to be positive on Rapid HIV I/II 
screening tests (Determine HIV-1/2, Inverness 
TM Medical Japan Co., Ltd and Uni-Gold , Trinity 
Biotech Plc, Ireland). Further tests like CD4, FBC, 
Liver and renal function tests are done on those with 
detected HIV DNA on polymerase chain reaction 
(PCR).
Anti-Retroviral Therapy (ART):  Infants initiated on 
ART on the ward or follow up clinics are reviewed 
fortnightly in the first month in out-patient clinic run 
by the unit. Those infants who were found to have 
BGC reactivation which was defined as swelling or 
ulceration at the BCG site and or ipsilateral axillary 
lymphadenopathy or ulceration are the subjects of 
this observational case series study. 
Needle aspirates from BCG site swelling and or 
ipsilateral axillary lymphnodes. Thin needle 
aspirate technique was used to aspirate BCG cold 
abscesses and axillary lymphnodes. The aspirates 
were taken into a plain bottle and transported to the 
TB Molecular laboratory within an hour. 
RESULTS
Five infants were identified in the unit during a 
period of two years. Table 1 shows the clinical 
characteristics of the infants. All the children who 
presented with BCG adenitis were young infants 
except one who was aged 7 months. Clinically at 
time of first presentation to hospital, the infants were 
very ill presenting with severe pneumonia and had 
no BCG scars (Table 1) 
Characteristic  Case 1  Case 2  Case 3  Case 4  Case 5 Case 6 
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ART & BCG IRIS details
 
3. ART initiation AZT/3TC/NVP d4T/3TC/NVP d4T/3TC/NVP AZT/3TC/NVP d4T/3TC/NVP d4T/3TC/NVP
4. Time of appearance of  left 
axillary lymphadenitis after ART 
initiation
2 weeks 4 weeks 4 weeks                  8 weeks 8 weeks 3 weeks
5. Management of BCG cold 
abscess (IRIS)
Continued ARVs Continued ARVs ATT started and continued 
ARVs. NVP replaced with 
ABC
Continued ARVs ATT started and continued 
ARVs. Replaced NVP with 
ABC
ATT started and 
continued ARVs. NVP 
replaced with ABC
Table 1: Clinical profile of young infants with IRIS due to BCG
ABC – Abacavir, AZT – Zidovudine, d4T – Stavudine, NVP – Niverapine




HIV DNA was detected on DBS of all the five
infants (Table 1). Their CD4 profiles showed that 
they were severely immunocompromised, CD4 less 
than 20%, except for Case no. 3 who had a CD4 
count of 30.9%. Of note on the full blood count was a 
marked monocytosis. 
Swellings at the BCG site and ipsilateral axillary 
lymphadenitis appeared 2 – 8 weeks after initiation 
of ARVs. Of note is that the mothers had infact noted 
the swellings much earlier and the upper limit of 8 
weeks is the time that the mothers became 
concerned and came on an unscheduled clinic visit.  
In  mycobacter ium spec ia t ion  ana lys is ,  
mycobacterium bovis, BCG strain was identified 
(Figure 1) than the wild mycobacterium 
tuberculosis species. Figure 2 shows a typical 
ipsilateral left axillary cold abscess as BCG 
injection site in young infant.
Figure 2: Typical Ipsilateral Left Axillary  Cold Abscess 
as BCG injection site in young infant. 
DISCUSSION
This observational case series report describes the 
risk of BCG vaccine causing axillary BCG 
lymphadenitis and cold abscesses in HIV vertically 
infected young infants initiated on ARVs. 
Speciation studies showed that these infants were 
infected with mycobacterium bovis, BCG strain 
 (Figure 1). All the young infants seen did not have a 
BCG scar at the time of initiation of ARVs implying 
that they failed to mount a delayed type 
hypersensitivity reaction to BCG vaccine due to 
immune-suppression. In vivo studies have 
previously conclusively shown that short course 
ARVs restored mycobacterium- specific T cell 
immunity in Macaque models co-infected with 
simian immunodeficiency virus and BCG (5). 
Therefore, lymphadenitis and cold abscesses in these 
young infants developed as a result of the restoration 
of immunity.  Anecdotally, some young infants who 
fail to develop BCG vaccine scar after 6 to 8 weeks of 
receiving a vaccine go on to receive a second dose 
and this practice which is widespread in Zambia 
should be discouraged. 
 
Studies elsewhere have consistently brought the 
safety of the current live attenuated BCG vaccines in 
HIV endemic areas under question. As ARVs 
become more widespread in Zambia, and indeed in 
sub-Saharan Africa, more young infants who are 
HIV vertically infected are likely to be at risk of BCG 
lymphadenitis and cold abscesses.  This can 
disseminate in BCG disease with fatal outcome.  
Some studies have described disseminated BCG 
6,7,8
disease in HIV infected infants .
Some BCG strains, like the Danish strain have been 
shown to be inherently resistant to isoniazide and 
acquire resistance to rifampicin during therapy has 
been demonstrated in HIV infected infants with BCG 
9
disease .  This has far reaching consequencies in the 
management of infants with BCG lymphadenothay / 
cold abscesses who may progress to BCG disease. 
Case no. 3 and 5 received anti-mycobacterial therapy 
(pyrazinamide, isoniazide, and rifampicin). On 
follow up, the patients responded well to treatment. 
In poor resource settings like Zambia, it may not be 
possible to diagnose BCG resistant strains to 
isoniazide or rifampicin particularly in those infants 
presenting outside the University Teaching Hospital 
in Lusaka where facilities for such diagnosis are not 
available. 
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Even in the face of increasing PMTCT coverage in 
Zambia, a new BCG vaccine to protect young infants 
from serious forms of tuberculosis like tuberculous 
meningitis and miliary tuberculosis is warranted.  
Furthermore, there is urgent need to replace the 
current live attenuated BCG vaccines with other 
10,11vaccines such as recombinant BCG vaccines .   
The current BCG vaccine given at birth or in early 
neonatal period is causing more harm than good 
particularly in remote rural settings where HIV 
infected infants are commenced on ARVs. These 
settings have no access to diagnostic facilities. The 
authors have attended to young infants with 
unresolving pneumonias and pyrexia of unknown 
origin which have empirically resolved on ATT. The 
only risk factor in most of these young infants has 
been BCG vaccine and lack of a BCG scar. The 
authors recommend that young infants being 
commenced on ART, should receive a standard 
course of ATT for the first 6 - 8 weeks. The benefits 
of this approach will be the prevention of IRIS due to 
BCG vaccine as BCG disease remains undiagnosed 
though diagnosis of BCG vaccine site abscess / 
ulceration and BCG adenitis in the ipsilateral axillar 
is obvious. 
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